Tag: tat2005 2 1

Tag: "tat2005" at biology news

TAT2005 - 3rd International Symposium on Targeted Anticancer Therapies

The 3rd International Symposium on Targeted Anticancer Therapies (TAT 2005) will be held in Amsterdam, The Netherlands, March 3-5, 2005. This conference will provide an update of recent developments concerning the new generation of rationally designed anticancer agents with well defined molecular targets in the cancer cell or the cancer cell's environment: targeted agents. The first representativ...

(Date:11/21/2009)... 20,2009 / b3c newswire / - KINAXO Biotechnologi...ound, gaining two new investors in the company, Le...eports that Jrgen Schumacher has been elected as a...NAXO shareholders Axel Ullrich, Hellmut Kirchner, ...al investors Mountain Partners, BioM, High-Tech Gr...

(Date:11/20/2009)...ed in the November 2009 issue of the journal GENE... how a family of genes (1-aminocyclopropane-1-carb...r production of ethylene. This gas affects many as...ays the foundation for future genetic manipulation... survive and thrive in difficult terrain, increase...

(Date:11/20/2009)...ments of plasma lipoprotein concentrations determi...R), researchers led by Daniel Chasman at Brigham a...Boston, MA, the Framingham Heart Study in Framingh...den and Oxford, England performed genetic associat...women of European ancestry from the Women,s Genome...

Breaking Biology News(10 mins):KINAXO Completes Financing Round to Enhance Biomarker Development 2 KINAXO Completes Financing Round to Enhance Biomarker Development 3 It's a gas: New discovery may lead to heartier, high-yielding plants 2 Genetic analysis helps dissect molecular basis of cardiovascular disease 2 The decision about the incision 3A Is midline or transverse better for abdominal surgery 3F 50399 1 The decision about the incision 3A Is midline or transverse better for abdominal surgery 3F 50399 2 A thirst for blood sparks toxic algal blooms 9065 1 A thirst for blood sparks toxic algal blooms 9065 2 Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial 50396 1 Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial 50396 2 Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial 50396 3 Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial 50396 4

[1] KINAXO Completes Financing Round to Enhance Biomarker Development [0] It's a gas: New discovery may lead to heartier, high-yielding plants [0] Genetic analysis helps dissect molecular basis of cardiovascular disease

Other Tagsessential 2 essential 3 essential 4 essential 5 essential 6 essential 7 essential 8 essential 9 essential 10 main 2 main 3 main 4 main 5 main 6 main 7 main 8 main 9 main 10 models 2 models 3 models 4 models 5 models 6 models 7 models 8 models 9 models 10 memories 2 memories 3 detailed 2 detailed 3 detailed 4 detailed 5 detailed 6 detailed 7 detailed 8 detailed 9 detailed 10 worst 2 worst 3 worst 4 worst 5

essential caribou main models hutchinson fred educationally rendel missouri diarrheal nino macromolecules memories detailed nile worst